Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00068874
Other study ID # P60AR049459
Secondary ID P60AR049459NIAMS
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2004
Est. completion date April 2007

Study information

Verified date May 2018
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate a program designed to help African American adolescents with lupus (systemic lupus erythematosus or SLE) cope with the disease.


Description:

SLE is the most common autoimmune connective tissue disease of childhood, affecting 5,000 to 10,000 children; the prevalence is higher among African American children and approximately 80% of sufferers are female. SLE is multisystemic in onset and has no known cure. Children with chronic illness have at least a two-fold increased risk for adjustment problems relative to their healthy peers. This risk is heightened among adolescents, who are at greater risk for psychopathology than are younger children. The diagnosis of a chronic medical condition during adolescence presents unique stressors, particularly for adolescents with lupus, who must endure bodily changes, including dermatological problems, hair loss, and changes in appearance due to medical therapies. Psychosocial processes, including methods of coping, expectations, and family functioning, are believed to mediate the influence of disease severity. This study will evaluate the effectiveness of a cognitive-based intervention to improve the quality of life of adolescents with SLE.

Participants in this study will be randomly assigned to either the cognitive-based intervention, a lupus education program, or a control group. Participants in the intervention group will have five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses. Caregivers will join the adolescent at the end of each training session to gain familiarity with the content reviewed in each session. The remaining two study visits are booster sessions during which the intervention material will be reviewed.

Participants in the education program will also have five study visits. Study visits will include disease-appropriate education materials. Caregivers will not be included in the education program. Participants will be assessed at study entry and Months 6, 9, and 12. Assessments will include questionnaires designed to measure disease severity, pain intensity, methods of coping, expectations of efficacy, social support, and adjustment.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date April 2007
Est. primary completion date April 2007
Accepts healthy volunteers No
Gender Female
Age group 12 Years to 18 Years
Eligibility Inclusion Criteria:

- Diagnosis of systemic lupus erythematosus (SLE)

Exclusion Criteria:

- Severe depression with suicidal thoughts

- Delirium, dementia, or cognitive impairment (e.g., Mini Mental Status Examination 24 or less)

- Severe intellectual impairment

- Terminal illness with a life expectancy of less than 1 year

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Coping skills and cognitive restructuring techniques
This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
Educational training
Participants will attend five study visits that will include disease-appropriate education materials.

Locations

Country Name City State
United States Ronald T. Brown, PhD Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BASC scores (measures of general adjustment) 4 years
Primary BASS Scores 4 years
Primary SPPA scores (perception of physical appearance and social 4 years
Primary competence) 4 years
Primary Peds-QL 4.0 and 3.0 (quality of life assessments) 4 years
Primary Psychological Adjustment 4 years
Primary BASC Scores 4 years
Secondary SLEDAI (measure of disease status) 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT06013995 - A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus Phase 1
Recruiting NCT03952624 - Patient-Centered Assessment of Symptoms and Outcomes
Terminated NCT01389895 - Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Phase 1
Completed NCT00710021 - Vitamin D3 in Systemic Lupus Erythematosus Phase 2
Completed NCT02265744 - Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Phase 2
Recruiting NCT06445127 - Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging) N/A
Completed NCT00581763 - Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies N/A
Recruiting NCT01172002 - Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis N/A
Completed NCT00299819 - Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT00054938 - Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) Phase 2
Terminated NCT03953690 - Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France
Recruiting NCT05715463 - Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity N/A
Enrolling by invitation NCT05321108 - Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupus N/A
Completed NCT00482989 - A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus Phase 1
Completed NCT00657189 - A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Completed NCT03402087 - A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients Phase 1
Completed NCT02857452 - Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire N/A
Terminated NCT03186794 - Aerobic Exercise in Women With Systemic Lupus Erythematosus N/A
Recruiting NCT05922722 - Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus